Nexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXperts

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of assay development and advanced laboratory testing is pleased to announce the signing of a definitive agreement, subject to conditions precedent, to acquire ImmunXperts. The closing of the transaction is expected by the end of March. Based in the Brussels South Charleroi Biopark within the town of Gosselies, ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in vitro functional and potency assays. These assays help pharmaceutical and biotech sponsors screen, select and optimize lead compounds before the initiation of in vivo trials.

NEOMED-LABS / Pacific Biomarkers Strengthens Its Immunology Franchise by Acquiring PAIRimmune

The recently merged NEOMED-LABS / Pacific Biomarkers (NLPBI), a leading immunology centric service provider specialized in assay development and clinical laboratory testing for vaccines and soluble large molecules, announced today the acquisition of PAIRimmune, Laval, Quebec, a non-GLP preclinical immunology service provider. With a legacy of more than 20 years in the assay development, immunogenicity and efficacy predictive in vitro and in vivo models, PAIRimmune’s CEO Danielle Poirier and her team have a solid reputation for outstanding science within the community. Since 2015, they work as a CRO with small Biotech, academic groups and the most prestigious vaccine and large molecule Pharma companies. This acquisition reinforces NLPBI’s ability to serve the needs of the health industry from the preclinical stage where this is so critical to develop robust data needed to take informed go/no-go decisions.